Streetbeat News

Products Services

ABBV

AbbVie has initiated the treatment of the first patient with its investigational drug ABBV-383 in the Phase 3 CERVINO study for relapsed/refractory multiple myeloma. The study will compare the efficacy, safety, and tolerability of ABBV-383 monotherapy against standard available therapies in patients who have undergone at least two prior treatments.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:02 pm

AMGN

Amgen announced positive Phase 3 trial results for UPLIZNA, showing an 87% reduction in IgG4-RD flares. This is the first randomized, placebo-controlled trial to demonstrate benefit in IgG4-RD, with all primary and key secondary endpoints met.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:01 pm

LMT

Lockheed Martin has signed an agreement with Firefly Aerospace for up to 25 Alpha rocket launches through 2029.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:00 pm

BTCUSD

Social Capital CEO Chamath Palihapitiya predicts Bitcoin could reach $500,000 by October 2025, based on historical price patterns following halving cycles. He highlights the potential for Bitcoin to replace gold and the impact of Bitcoin ETFs on adoption.

Portfolio Pulse from Murtuza Merchant

June 05, 2024 | 12:59 pm

GFS

ElevATE Semiconductor and GlobalFoundries (NASDAQ:GFS) have announced a partnership to produce high-voltage chips at GF's Vermont facility. These chips, designed by ElevATE and manufactured using GF's 7HV technology, are crucial for commercial semiconductor testing equipment and aerospace and defense systems.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:43 pm

ISRG

Intuitive Surgical (NASDAQ: ISRG) received FDA clearance for revised labeling of its da Vinci X and Xi systems for radical prostatectomy, based on real-world evidence showing similar long-term survival rates to non-robotic procedures.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:42 pm

STSS

Sharps Technology has secured exclusivity to purchase InjectEZ assets from Nephron Pharmaceuticals with a $1 million escrow deposit. The acquisition will establish Sharps' position in the prefillable syringe industry, with product orders totaling over $200 million expected in the first five years. Shipments are planned to begin by Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:40 pm

ADIL

Adial Pharmaceuticals shares are trading higher after the company announced that the first patient has been dosed in its pharmacokinetics study of AD04 for Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:40 pm

SHOT

Safety Shot, Inc. (NASDAQ: SHOT) has announced its expansion into New York and New Jersey through a partnership with Prime CSB, as part of its larger Northeast expansion plan.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:39 pm

GCTK

Glucotrack has completed its second long-term preclinical study for its continuous blood glucose monitor, showing a mean absolute relative difference of 4.7% at day 90.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:38 pm